

Please type a plus sign (+) in this box

PTO/SB (12-97)

OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO

INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/379,149
Filing Date	March 4, 2003
First Named Inventor	Victoria M. Richon and Judy H. Chiao
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	24852-501

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
JDA	A1	5,055,608	10/08/91	Marks et al.	560	169	06/30/89
	A2	5,175,191	12/29/92	Marks et al.	514	575	05/14/90
	A3	5,369,108	11/29/94	Breslow et al.	514	266	10/04/91
	A4	5,608,108	03/04/97	Marks et al.	562	621	04/17/95
	A5	5,700,811	12/23/97	Breslow et al.	514	314	05/19/94
	A6	5,773,474	06/30/98	Breslow et al.	514	616	06/07/95
↓	A7	5,932,616	08/13/99	Breslow et al.	514	532	04/04/94
	A8	6,087,367	06/11/00	Breslow et al.	514	266	05/18/99
JDA	A9	6,511,990	01/28/03	Breslow et al.	514	314	08/24/00

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
JDA	B1	WO 98/40080	Beacon Laboratories, L.L.C.	September 17, 1998	X
	B2	WO 00/21979	Fujisawa Pharmaceutical Co., LTD	April 20, 2000	X
	B3	WO 00/71703	Methylgene, Inc.	November 30, 2000	X
	B4	WO 01/18171	Sloan-Kettering Institute for Cancer Research & The Trustees of Columbia University in the City of New York	March 15, 2001	X
	B5	WO 01/38322	Methylgene, Inc.	May 31, 2001	X
	B6	WO 01/70675	Methylgene, Inc.	September 27, 2001	X
↓	B7	WO 02/22577	Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.	March 21, 2002	X
↓	B8	WO 02/30879	Prolifix Limited	April 18, 2002	X
JDA	B9	WO 02/46144	F. Hoffmann-La Roche AG	June 13, 2002	X

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
JDA	C1	Andrews et al. (2000). <i>Intl. J. Parasitol.</i> 30: 761-768.
	C2	Archer et al. (1998). <i>Proc. Natl. Acad. Sci. USA</i> 95: 6791-6796.
	C3	Bhalla et al. (2002). "Co-treatment With The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances the Cytotoxic Effects of Gleevec and Arsenic Trioxide (AT) Against Bcr-Abl Positive Human Leukemia Cells." <i>American Society of Hematology, 44<sup>th</sup> Meeting of the American Society of Hematology, Abstract 4611.</i>
	C4	Butler et al. (2000). <i>Cancer Res.</i> 60: 5165-5170.
↓	C5	Butler et al. (2001). <i>Clinical Cancer Res.</i> 7: 962-970.
	C6	Butler et al. (2002). <i>Proc. Natl. Acad. Sci. USA</i> 99: 11700-11705.
JDA	C7	Coffey et al. (2000). <i>Medical and Pediatric Oncology</i> 35: 577-581.

FEB 26 2004

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
JDA	C8	Coffey et al. (2001). <i>Cancer Res.</i> <u>61</u> : 3591-3594.
	C9	Cohen et al. (1999). <i>Anticancer Res.</i> <u>19</u> : 4999-5006.
	C10	Cohen et al. (2002). <i>Anticancer Res.</i> <u>22</u> : 1497-1504.
	C11	Curtin (2002). <i>Exp. Opin. Ther. Patents</i> <u>12</u> : 1375-1384.
	C12	Dressel (2000). <i>Anticancer Res.</i> <u>20</u> : 1017-1022.
	C13	Fei et al. (2002). "Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptosis of Human Acute Lymphoid Leukemia Cells." <i>American Society of Hematology</i> , 44 <sup>th</sup> Meeting of the American Society of Hematology Abstract No. 4602.
	C14	Feinman et al. (2002). "The Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, Induces Apoptosis of Multiple Myeloma Cells." <i>American Society of Hematology</i> , 44 <sup>th</sup> Meeting of the American Society of Hematology, Abstract No. 3195.
	C15	Finnin et al. (1999). <i>Nature</i> <u>401</u> : 188-193.
	C16	Furamai et al. (2001). <i>Proc. Natl. Sci. USA</i> <u>98</u> : 87-92.
	C17	Grunstein (1997). <i>Nature</i> <u>389</u> : 349-352.
	C18	He et al. (2001). <i>J. Clin. Investigation</i> <u>108</u> : 1321-1330.
	C19	Hockly et al. (2003). <i>Proc. Natl. Acad. Sci. USA</i> <u>100</u> : 2041-2046.
	C20	Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." <i>American Society of Clinical Oncology</i> , Abstract No. 344.
	C21	Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good bioavailability and biologic activity." <i>American Society of Clinical Oncology</i> , 38 <sup>th</sup> Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstract No. 1831.
	C22	Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)." <i>European J. Cancer</i> <u>38</u> (Suppl. 7): 88, Abstract No. 286.
	C23	Kim et al. (1999). <i>Oncogene</i> <u>18</u> : 2461-2470.
	C24	Kohge et al. (1998). <i>Biochem. Pharmacol.</i> <u>56</u> : 1359-1364.
	C25	Komatsu et al. (2001). <i>Cancer Res.</i> <u>61</u> : 4459-4466.
	C26	Kouraklis and Theocharis (2002). <i>Curr. Med. Chem.-Anti-Cancer Agents</i> <u>2</u> : 477-484.
	C27	Lee et al. (2001). <i>Cancer Res.</i> <u>61</u> : 931-934.
	C28	Lin et al. (1998). <i>Nature</i> <u>391</u> : 811-814.
	C29	Mai et al. (2001). <i>OPPI Briefs</i> <u>33</u> : 391-394
	C30	Marks et al. (2000). <i>J. of the Natl. Cancer Institute</i> <u>92</u> : 1210-1215.
	C31	Marks et al. (2001). <i>Clinical Cancer Res.</i> <u>7</u> : 759-760.
	C32	Marks et al. (2001). <i>Curr. Opin. In Oncology</i> <u>13</u> : 477-483.
	C33	Marks et al. (2001). <i>Nature Reviews</i> <u>1</u> : 194-202.
	C34	Miller et al. (2003). <i>J Med Chem.</i> <u>46</u> : 5097-5116.
	C35	Munster et al. (2001). <i>Cancer Res.</i> <u>61</u> : 8492-8497.
	C36	O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHL0 and hodgkin's disease (HD))." <i>American Society of Clinical Oncology</i> , December 6-10, 2002, Abstract No. 4742.
	C37	Qui et al. (2000). <i>Mol. Biol. Cell</i> <u>11</u> : 2069-2083.
	C38	Richon et al. (1996). <i>Proc. Natl. Acad. Sci. USA</i> <u>93</u> : 5705-5708.
	C39	Richon et al. (1998). <i>Proc. Natl. Acad. Sci. USA</i> <u>95</u> : 3003-3007.
	C40	Richon et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> <u>97</u> : 10014-10019.
	C41	Richon and O'Brien (2002). <i>Clinical Cancer Res.</i> <u>8</u> : 662-664.
	C42	Saito et al. (1999). <i>Proc. Natl. Acad. Sci. USA</i> <u>96</u> : 4592-4597.
JDA	C43	Sgouros et al. (2002). "Synergistic interaction of Suberoylanilide Hydroxamic Acid (SAHA) and



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
		Radiation in Human Prostate Tumor Spheroids." <i>American Society of Clinical Oncology, Abstract No. 105.</i>
JDA	C44	Stowell et al. (1995). <i>J. Med. Chem.</i> <u>38</u> : 1411-1413.
	C45	Su et al. (2000). <i>Cancer Res.</i> <u>60</u> : 3137-3142.
	C46	Suzuki et al. (1999). <i>J. Med. Chem.</i> <u>42</u> : 3001-3003.
	C47	Van Lint et al. (1996). <i>Gene Expression</i> <u>5</u> : 245-253.
	C48	Vrana et al. (1999). <i>Oncogene</i> <u>18</u> : 7016-7025.
	C49	Webb et al. (1999). <i>J. Biol. Chem.</i> <u>274</u> : 14280-14287.
	C50	Yoshida et al. (1990). <i>J. Biol. Chem.</i> <u>265</u> : 17174-17179.
	C51	Yoshida et al. (1995). <i>BioEssays</i> <u>17</u> : 423-430.
	C52	Zhou et al. (1999). <i>Gene</i> <u>233</u> : 13-19.
	C53	Zhou et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> <u>97</u> : 1056-1061.
✓	C54	Zhou et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> <u>97</u> : 14329-14333.
JDA	C55	Zhou et al. (2001). <i>Proc. Natl. Acad. Sci. USA</i> <u>98</u> : 10572-10577.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/James Anderson/	Date Considered	12/07/2006
--------------------	------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail Label No.: EV781047971US  
Date of Deposit: July 25, 2006

PAGE 1 of 4

O P E  
JUL 25 2006  
P T O  
U S P S  
P E N T & M A D E M A S  
Please type a plus sign (+) in this box

PTO/SB (12-97)  
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	10/665,079
		Filing Date	09/16/03
		First Named Inventor	Bacopoulos
		Group Art Unit / Confirmation No.	1614 / 6072
		Examiner Name	Cybille Delacroix-Muirheid
		Attorney Docket Number	24852-501 CIP5

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
JDA	A25*	4,690,918	09/01/87	Beppu, et al.			
	A26*	5,654,333	08/05/97	The United States of America as represented by the Department of Health and Human Services			
	A27*	6,239,176	05/29/01	Beacon Laboratories, Inc. et al.			
	A28*	6,262,116	07/17/01	Sloan-Kettering Institute for Cancer Research			
	A29*	6,451,334	09/17/02	Perrine			
	A30*	6,495,719	12/17/02	CircaGen Pharmaceutical			
	A31*	2003/0114525	06/19/03	Kammer, et al.			
	A32*	2004/0132643	07/08/04	Fojo, et al.			
↓	A33*	2004/0167184	08/26/04	Wiech, et al.			
JDA	A34	6,495,719	12/17/02	Lan-Hargest, et al.			

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No
JDA	B14*	WO 98/39965	Beacon Laboratories, LLC	09/17/98	X
JDA	B15*	WO 02/15921	The Government of the United States of America	02/28/02	X
JDA	B16*	WO 02/055017	Wake Forest University	07/18/02	X

NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
JDA	C83*	"Aton Pharma, Inc. Announces Initiation of Two Phase II Trials to Evaluate Efficacy of HDAC Inhibitor SAHA", October 30, 2002.
JDA	C84*	"Aton Pharma, Inc. Announces Phase I Clinical Trial of SAHA in Advanced Leukemias", July 1, 2003.
JDA	C85*	"Aton Pharma, Inc. Appoints Judy H. Chiao, M.D., as Vice President, Oncology Clinical Research and Development", September 20, 2002.
JDA	C86*	"Aton Pharma, Inc. Presents Phase I Trial Data of Anti-Cancer Agent SAHA in Patients with hematological Malignancy at ASCO", June 2, 2003.
JDA	C87*	"Aton Pharma, Inc. Presents Phase I Trial Data on Anti-Cancer Agent SAHA at EORTC/NCI/AACR Symposium", November 21, 2002.

NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
JDA	C88*	"Aton Pharma, Inc. Received Orphan Drug Designation for SAHA in Multiple Myeloma and Initiates Phase I Trial", October 13, 2003.
	C89*	"Aton Pharma, Inc. Reports on Phase I Trial of SAHA", August 14, 2002.
	C90*	Adhikari, D et al., Proceedings of the American Association for Cancer Research Annual Meeting, (1998), Vol. 39, p 312, "Radiosensitization of Lymphoma Cell Lines by Sodium Butyrate".
	C91*	Alexandrov, I et al., FEBS Letters, (1998), Vol. 434, pp 209-214, "Sodium Butyrate Suppresses Apoptosis in Human Burkitt Lymphomas and Murine Plasmacytomas Bearing c-myc Translocations".
	C92*	Almenara, J et al., Leukemia (2002), Vol. 16, pp 1331-1343, "Synergistic Induction of Mitochondrial Damage and Apoptosis in Human Leukemia Cells by Flavopiridol and the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA)".
	C93*	Amin HM et al., British Journal of Haematology (2001), Vol. 115, pp 287-297, "Histone Deacetylase Inhibitors Induce Caspase-Dependent Apoptosis and Downregulation of Daxx in Acute Promyelocytic Leukaemia with t(15;17)".
	C94*	Aron, JL et al., Blood (2003), Vol. 102, No. 2, pp 652-658, "Depsipeptide (FR901228) Induces Histone Acetylation and Inhibition of Histone Deacetylase in Chronic Lymphocytic Leukemia Cells Concurrent With Activation of Caspase 8-mediated Apoptosis and Down-Regulation of c-FLIP Protein".
	C95*	Benoit, NE et al., Immunopharmacology, (1996), Vol. 35, pp 129-139, "Increased inhibition of Proliferation of Human B Cell Lymphomas Following Litigation of CD40, and Either CD19, CD20, CD95 or Surface Immunoglobulin".
	C96*	Bode, J et al., Journal of Interferon Research, (1982), Vol. 2, No. 2, pp 159-166, "Links Between Effects of Butyrate on Histone Hyperacetylation and Regulation of Interferon Synthesis in Namalva and FS-4 Cell Lines".
	C97*	Buckley, AR et al., Cell Growth & Differentiation (1996), Vol. 7, pp 1713-1721, "Alterations in pim-1 and c-myc Expression Associated with Sodium Butyrate-induced Growth Factor Dependency in Autonomous Rat Nb2 Lymphoma Cells".
	C98*	Buckley, AR et al., Proceedings of the American Association for Cancer Research Annual Meeting, (1997), Vol. 38, p 193, "Reversal of Apoptosis Resistance by Butyrate in rat Nb2 Lymphoma Cells".
	C99*	Byrd, JC et al., Blood (1999), Vol. 94, No. 4, pp 1401-1408, "Depsipeptide (FR901228): A Novel Therapeutic Agent with Selective, In Vitro Activity Against Human B-Cell Chronic Lymphocytic Leukemia Cells".
	C100	Cao, et al. (2001), Am. J. Respir. Cell Mol. Biol., 25:562-8, "Histone Deacetylase Inhibitor Downregulation of bcl-xL Gene Expression Leads to Apoptotic Cell Death in Mesothelioma".
	C101*	Carducci, MA et al., Clinical Cancer Research (2001), Vol. 7, No. 10, pp 3047-3055, "A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule".
	C102*	Dear, AE et al., Biochimica et Biophysica Acta, (2000), Vol. 1492, pp 15-22, "The Novel Anti-Tumour Agent Oxamflatin Differentially Regulates Urokinase and Plasminogen Activator Inhibitor Type 2 Expression and Inhibits Urokinase-Mediated Proteolytic Activity".
	C103*	Desai, D et al., Anticancer Research (2003), Vol. 23, pp 499-504, "Chemopreventive Efficacy of Suberoylanilide Hydroxamic Acid (SAHA) Against 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced Lung Tumorigenesis in Female A/J Mice".
	C104*	Dhordain, P et al., Nucleic Acids Research, (1998), Vol. 26, No. 20, pp 4645-4651, "The LAZ3(BCL-6) Oncoprotein Recruits a SMRT/mSIN3A/Histone Deacetylase Containing Complex to Mediate Transcriptional Repression".
	C105*	Edelman, MJ et al., Cancer Chemotherapy and Pharmacology (2003), Vol. 51, pp 439-444, "Clinical and Pharmacologic Study of Tributyryl: An Oral Butyrate Prodrug".
↓	C106*	Feinman, R et al., Blood (2002), Vol. 100, No. 11, pp Abstract 3195, "The Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, Induces Apoptosis of Multiple Myeloma Cells".
JDA	C107*	Filippovich, I et al., Biochemical and Biophysical Research Communications, (1994), Vol. 198, pp 257-265, "Butyrate Induced Apoptosis in Lymphoid Cells Preceded by Transient Over-Expression of HSP70 mRNA".

NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
JDA	C108*	Foss, FM et al., Blood, (1993), Vol. 82, No. 10, Suppl. 1, p 564A, "Biomodulatory Effects of Butyric Acid Derivatives on Leukemia and Lymphoma Cells".
	C109	Gediya, et al., J. Med. Chem. (2005), Vol. 48, pp 5047-5051, "A New Simple and High-Yield Synthesis of Suberoylanilide Hydroxamic Acid and Its Inhibitory Effect Alone or in Combination with Retinoids on Proliferation of Human Prostate Cancer Cells".
	C110*	Gelmetti, V et al., Molecular and Cellular Biology (1998), Vol. 18, No. 12, pp 7185-7191, "Aberrant Recruitment of the Nuclear Receptor Corepressor-Histone Deacetylase Complex by the Acute Myeloid Leukemia Fusion Partner ETO".
	C111*	Gerbitz, A, Oncogene, (1999), Vol. 18, pp 1745-1753, "Deregulation of the Proto-Oncogene c-myc Through t(8;22) Translocation in Burkitt's Lymphoma".
	C112*	Gilbert, J et al., Clinical Cancer Research (2001), Vol. 7, No. 8, pp 2292-2300, "A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies".
	C113*	Grisolano, JL et al., Proceedings of the National Academy of Sciences (2003), Vol. 100, No. 16, pp 9506-9511, "An Activated Receptor Tyrosine Kinase, TEL/PDGFbetaR, Cooperates with AML1/ETO to Induce Acute Myeloid Leukemia in Mice".
	C114*	Harris, NL et al., Blood (1994), Vol. 84, No. 5, pp 1361-1392, "A Revised European-American Classification of Lymphoid Neoplasms: A Proposal From the International Lymphoma Study Group".
	C115*	Jaboin, J et al., Cancer Research (2002), Vol. 62, No. 21, pp 6108-6115, "MS-27-275, an Inhibitor of Histone Deacetylase, Has Marked in Vitro and in Vivo Antitumor Activity against Pediatric Solid Tumors".
	C116*	Kurita-Ochiai, T et al., Infection and Immunity, (1998), Vol. 66, No. 6, pp 2587-2594, "Volatile Fatty Acid, Metabolic By-Product of Periodontopathic Bacteria, Induces Apoptosis in WEHI 231 and RAJI B Lymphoma Cells and Splenic B Cells".
	C117*	Liu, Z et al., Journal of Cancer Research and Clinical Oncology, (1998), Vol. 124, pp 541-548, "Synergistic Effect of Epstein-Barr Virus and Tumor Promoters on Induction of Lymphoma and Carcinoma in Nude Mice".
	C118*	Madisen, L et al., Molecular and Cellular Biology, (1998), Vol. 18, No. 11, pp 6281-6292, "The Immunoglobulin Heavy Chain Locus Control Region Increases Histone Acetylation along Linked c-myc Genes".
	C119*	Niitsu, N et al., Molecular Pharmacology, (2000), Vol. 58, pp 27-36, "Anticancer Derivative of Butyric Acid (Pivaloyloxymethyl Butyrate) Specifically Potentiates the Cytotoxicity of Doxorubicin and Daunorubicin Through the Suppression of Microsomal Glycosidic Activity".
	C120*	Orr, D et al., 2000 ASCO Annual Meeting, Abstract No. 763, "Phase I Pharmacokinetic (PK) Study of CI-994 in Combination with Gemcitabine (GEM) in Patients with Advanced Solid Tumors".
	C121*	Polack, A et al., The EMBO Journal, (1993), Vol. 12, No. 10, pp 3913-3920, "Regulatory Elements in the Immunoglobulin Kappa Locus Induce c-myc Activation and the Promoter Shift in Burkitt's Lymphoma Cells".
	C122*	Rezuke, WN et al., Clinical Chemistry (1997), Vol. 43, No. 10, pp 1814-1823, "Molecular Diagnosis of B- and T-cell Lymphomas: Fundamental Principles and Clinical Applications".
	C123*	Rottlieb, C et al., International Journal of Cancer, (1995), Vol. 62, pp 697-702, "Among 17 Inducers of Differentiation Only Sodium Butyrate Causes a Permanent Down-Regulation of c-myc in Burkitt's Lymphoma".
	C124*	Rottlieb, C et al., International Journal of Cancer, (1996), Vol. 67, pp 724-729, "Structure-Activity Relationship of 17 Structural Analogues of N-Butyric Acid Upon c-myc Expression".
↓	C125*	Rubio, MA et al., Blood, (1995), Vol. 86, No. 10, pp 3715-3724, "Granulocyte-Macrophage Colony-Stimulating Factor, Phorbol Ester, and Sodium Butyrate Induce the CD11c Integrin Gene Promoter Activity During Myeloid Cell Differentiation".
JDA	C126*	Schrump, DS et al., Clinical Lung Cancer (2002), Vol. 4, No. 3, pp 186-192, "Phase I Study of Sequential Deoxyazacytidine/depsipeptide Infusion in Patients with Malignancies Involving Lungs or Pleura".

NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
JDA	C127*	Vrana JA et al., Oncogene 1999), Vol. 18, pp 7016-7025, "Induction of Apoptosis in U937 Human Leukemia Cells by Suberoylanilide Hydroxamic Acid (SAHA) Proceeds Through Pathways That are Regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53".
	C128	Waheed et al. (2000), Proceedings of the American Association for Cancer Research Meeting, (91st, San Francisco, 41:808, Abstract 5135, "The Histone Deacetylase Inhibitor FR 901228 Induces SV40T/T Antigen Expression and P53 Hyperacetylation in Human Pleural Mesothelioma Cells".
	C129*	Watanabe, M et al., Cancer Research (1990), Vol. 50, pp 3245-3248, "Effect of liposomes containing sodium butyrate conjugated with anti-CD19 monoclonal antibody on in vitro and in vivo growth of malignant lymphoma".
	C130	Weiser et al. (2001), J. Immunotherapy, 24:151-61, "Sequential 5-Aza-2'-deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells and Facilitates Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1".
	C131*	Yu, C et al., Cancer Research (2001), Vol. 63, pp 2118-2126, "Histone Deacetylase Inhibitors Promote ST1571-Mediated Apoptosis in ST1571-Sensitive and -Resistant Bcr/Abl+ Human Myeloid Leukemia Cells".
	C132*	Zhang, M et al., Cell Stress & Chaperones, (1998), Vol 3, No. 1, pp 57-66, "Heat-Induced Proteolysis of HSF Causes Premature Deactivation of the Heat Shock Response in Nb2 Lymphoma Cells".
	C133	Bruner, RJ et al., Blood (2002), 44th Annual Meeting of the American Society of Hematology, Vol. 100, No. 11, pp Abstract No. 1492, "Phase I trial of the histone deacetylase inhibitor depsipeptide (FR901228) in fludarabine refractory chronic lymphocytic leukemia".
	C134	Guo, F et al., American Society of Hematology, (December 6-10, 2002), p 268b, Abstract 4602 "Co-treatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances Apo-2L/TRAIL-induced death inducing signaling complex and apoptosis of human acute lymphoid leukemia cells".
	C135	Heaney, M et al., 2003 ASCO Annual Meeting, Proceedings of the American Society of Clinical Oncology, (2003) Vol. 22, p 577, Abstract 2321, "Clinical experience with the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) in heavily pre-treated patients with hematological malignancies".
	C136	Marcucci, G et al., Blood, (2002), 44th Annual Meeting of the American Society of Hematology", Vol. 100, No. 11, pp Abstract No. 317, "Phase I trial of the histone deacetylase inhibitor depsipeptide (FR901228) in acute myeloid leukemia (AML)".
	C137	Nimmanapalli, R et al., American Society of Hematology, (December 6-10, 2002), 14 pages, "Co-treatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances Gleevec-induced apoptosis of Bcr-Abl positive human acute leukemia cells".
	C138	Nimmanapalli, R et al., Blood (2003), Vol. 101, No. 8, pp 3236-3239, "Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells".
↓	C139	Tabe, Y et al., Blood (2002), 44th Annual Meeting of the American Society of Hematology, Vol. 100, No. 11, pp Abstract No. 3028, "Effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) and DNA methylation inhibitor 5-aza-2'-deoxycytidine (DAC) on the transcriptional activation of RARbeta and p21WAF in acute promyelocytic leukemia cells".
JDA	C140	Zhang, C et al, The Journal of Investigative Dermatology (2003), Vol. 121, No. 1, pp Abstract 1189, "The histone inhibitor suberoylanilide hydroxamic acid induces apoptosis in cutaneous T cell lymphoma cells".

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/650,025, filed August 26, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/James Anderson/	Date Considered	12/07/2006
--------------------	------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.